SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pollard JK, Scott JR, Branch DW. Outcome of children born to women treated during pregnancy for the antiphospholipid syndrome. Obstet Gynecol 1992; 80: 3658.
  • 2
    Botet F, Romera G, Montagut P, Figueras J, Carmona F, Balasch J. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinatal Med 1997; 25: 1926.
  • 3
    Brewster JA, Shaw NJ, Farqharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinatal Med 1999; 27: 1837.
  • 4
    Ruffatti A, Dalla Barba B, Del Ross T, Vettorato F, Rapizzi E, Tonello M, et al. Outcome of fifty-five newborns of antiphospholipid antibody–positive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol 1998; 16: 60510.
  • 5
    Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus 2007; 16: 63441.
  • 6
    Boffa MC, Aurousseau MH, Lachassinne E, Dauphin H, Fain O, Le Toumelin P, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus 2004; 13: 7137.
  • 7
    Ruffatti A, Tonello M, Del Ross T, Cavazzana A, Grava C, Noventa F, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96: 33741.
  • 8
    Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123: 4827.
  • 9
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 10
    Ruffatti A, Orsini A, Di Lenardo L, Nardelli GB, Patrassi GM, Truscia D, et al. A retrospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid-related fetal loss. Clin Exp Rheumatol 1997; 15: 499505.
  • 11
    Ruffatti A, Favaro M, Tonello M, De Silvestro G, Pengo V, Fais G, et al. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus 2005; 14: 1208.
  • 12
    Ruffatti A, Marson P, Pengo V, Favaro M, Tonello M, Bortolati M, et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome: a report of 9 cases and a review of the literature. Autoimmun Rev 2007; 6: 196202.
  • 13
    Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni PL, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on Antiphospholipid Antibodies. Thromb Res 2004; 114: 5538.
  • 14
    Reber G, Tincani A, Sanmarco M, de Moeloose P, Boffa MC, and the Standardization Group of the European Forum on Antiphospholipid Antibodies. Proposals for the measurement of anti–β2-glycoprotein I antibodies. J Thromb Haemost 2004; 2: 18602.
  • 15
    Brandt JT, Triplett DA, Alvin B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant. Thromb Haemost 1995; 74: 118590.
  • 16
    Saling E, Luthje J, Schreiber M. Efficient and simple program including community-based activities for prevention of very early premature birth. In: KurjakA, ChervenakFA, editors. Textbook of perinatal medicine. Boca Raton (FL): CRC Press; 2006. p. 140111.